Mallon Mark 4
4 · IRONWOOD PHARMACEUTICALS INC · Filed May 13, 2020
Insider Transaction Report
Form 4
Mallon Mark
DirectorChief Executive Officer
Transactions
- Sale
Class A Common Stock
2020-05-11$10.35/sh−23,206$240,182→ 501,280 total
Footnotes (1)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019.